Holen Sie sich die Stockscreener-App
15.67
0.87%
-0.14
Kalvista Pharmaceuticals Inc Aktie (KALV) Neueste Nachrichten
What analysts say about KalVista Pharmaceuticals Inc. stockRapidly growing investment returns - Autocar Professional
KalVista Pharmaceuticals Inc. Stock Analysis and ForecastRobust investment performance - jammulinksnews.com
What drives KalVista Pharmaceuticals Inc. stock priceOutstanding yields - jammulinksnews.com
Is KalVista Pharmaceuticals Inc. a good long term investmentRapid return acceleration - jammulinksnews.com
Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com
Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP By Investing.com - Investing.com South Africa
Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP - Investing.com India
Kalvista's Ekterly OK'd as on-demand HAE swelling attack treatment in UK - Angioedema News
(KALV) Proactive Strategies - news.stocktradersdaily.com
JMP reiterates Market Outperform rating on Kalvista stock after UK approval By Investing.com - Investing.com South Africa
JMP reiterates Market Outperform rating on Kalvista stock after UK approval - Investing.com Nigeria
KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - BioSpace
KalVista Pharmaceuticals Gets UK Approval for Hereditary Angioedema Treatment - MarketScreener
KalVista Pharmaceuticals announces UK MHRA approval of Ekterly (sebetralstat) - MarketScreener
KalVista gets UK nod for Ekterly (KALV:NASDAQ) - Seeking Alpha
UK approves first oral treatment for hereditary angioedema attacks By Investing.com - Investing.com Canada
(sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire
MHRA approves Ekterly to treat HAE - The Pharma Letter
KalVista Pharmaceuticals Wins UK Approval for Hereditary Angioedema Treatment - MarketScreener
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Have Insiders Sold KalVista Pharmaceuticals Shares Recently? - simplywall.st
The week in pharma: action, reaction and insight – week to July 11 - The Pharma Letter
Kalvista stock maintains Buy rating at H.C. Wainwright on favorable Ekterly label - Investing.com Nigeria
KalVista:HC Wainwright Raises PT to $27, Maintains Buy Rating - AInvest
Kalvista Pharma chief development officer sells $474k in shares By Investing.com - Investing.com Canada
KalVista Pharmaceuticals: EKTERLY Launch and Financial Update - TipRanks
Kalvista Pharma chief development officer sells $474k in shares - Investing.com Australia
Kalvista Pharma CEO Palleiko sells $517k in shares By Investing.com - Investing.com South Africa
Kalvista Pharma CEO Palleiko sells $517k in shares - Investing.com Australia
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results - BioSpace
KalVista price target raised to $27 from $19 at Citizens JMP - MSN
KalVista Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Leerink Partners reiterates Outperform rating on Kalvista stock as Ekterly launch begins By Investing.com - Investing.com South Africa
Leerink Partners reiterates Outperform rating on Kalvista stock as Ekterly launch begins - Investing.com Nigeria
KalVista Shares Fall After Fiscal 2025 Results - MarketScreener
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally? - TradingView
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended April 30, 2025 - MarketScreener
4.74%
0.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):